Research programme: chemokine receptor antagonists - BiotherapixAlternative Names: Btx 501; Btx 502; Diakines
Latest Information Update: 16 Jul 2016
At a glance
- Originator Biotherapix
- Mechanism of Action Chemokine receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Spain
- 30 Aug 2007 Preclinical trials in Inflammation in Spain (unspecified route)